Cargando…

Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine

Neisseria meningitidis serogroup B is the most prevalent cause of invasive meningococcal disease in Europe and members of laboratories working on meningococci are at risk due to frequent handling. Recommendation for anti-meningococcal vaccination among these workers has been recently updated upon th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Eva, Terrade, Aude, Taha, Muhamed-Kheir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2016
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360120/ https://www.ncbi.nlm.nih.gov/pubmed/27808594 http://dx.doi.org/10.1080/21645515.2016.1241358

Ejemplares similares

Product review on the IMD serogroup B vaccine Bexsero®
por: Deghmane, Ala-Eddine, et al.
Publicado: (2022)

Haemophilus influenzae type b (Hib) seroprevalence in France: impact of vaccination schedules
por: Hong, Eva, et al.
Publicado: (2021)

Modelling the cost-effectiveness of catch-up ‘MenB’ (Bexsero) vaccination in England
por: Christensen, Hannah, et al.
Publicado: (2017)

The Serogroup B Meningococcal Vaccine Bexsero Elicits Antibodies to Neisseria gonorrhoeae
por: Semchenko, Evgeny A, et al.
Publicado: (2019)

Genetic Diversity and Levels of Expression of Factor H Binding Protein among Carriage Isolates of Neisseria meningitidis
por: Lemée, Ludovic, et al.
Publicado: (2014)

Crystal structures of human Fabs targeting the Bexsero meningococcal vaccine antigen NHBA
por: Maritan, Martina, et al.
Publicado: (2017)

Hyperinvasive Meningococci Induce Intra-nuclear Cleavage of the NF-κB Protein p65/RelA by Meningococcal IgA Protease
por: Besbes, Anissa, et al.
Publicado: (2015)

Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study
por: Christensen, Hannah, et al.
Publicado: (2014)

Laboratory worker knowledge, attitudes and practices towards smallpox vaccine
por: Benzekri, Noelle, et al.
Publicado: (2010)

The Phosphocarrier Protein HPr Contributes to Meningococcal Survival during Infection
por: Antunes, Ana, et al.
Publicado: (2016)

Immunogenicity of inactivated COVID-19 vaccines at different vaccination intervals
por: Li, Juan, et al.
Publicado: (2021)

Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis
por: Gasparini, Roberto, et al.
Publicado: (2016)

Health and Economic Outcomes of Introducing the New MenB Vaccine (Bexsero) into the Italian Routine Infant Immunisation Programme
por: Tirani, Marcello, et al.
Publicado: (2015)

Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine
por: Montalban, Cecilia, et al.
Publicado: (2017)

Impact of mandatory vaccination against serogroup C meningococci in targeted and non-targeted populations in France
por: Taha, Samy, et al.
Publicado: (2022)

Invasive Bacterial Infections in Subjects with Genetic and Acquired Susceptibility and Impacts on Recommendations for Vaccination: A Narrative Review
por: Deghmane, Ala-Eddine, et al.
Publicado: (2021)

Progressive Decrease in the Potential Usefulness of Meningococcal Serogroup B Vaccine (4CMenB, Bexsero®) in Gipuzkoa, Northern Spain
por: Pérez-Trallero, Emilio, et al.
Publicado: (2014)

The Bexsero Neisseria meningitidis serogroup B vaccine antigen NHBA is a high-affinity chondroitin sulfate binding protein
por: Mubaiwa, Tsitsi D., et al.
Publicado: (2018)

Immunogenicity and safety of an intramuscular split-virion quadrivalent inactivated influenza vaccine in individuals aged ≥ 6 months in India
por: Agarkhedkar, Sharad, et al.
Publicado: (2019)

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China versus a comparator influenza vaccine: a phase IV randomized study
por: Hu, Yuemei, et al.
Publicado: (2019)

Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients
por: Chevallier, Patrice, et al.
Publicado: (2021)

Yellow fever vaccination in Brazil: Short-term safety and immunogenicity in juvenile autoimmune rheumatic diseases
por: Emi Aikawa, Nádia, et al.
Publicado: (2021)

Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults
por: Scaggs Huang, Felicia, et al.
Publicado: (2020)

COVID-19 vaccine uptake among healthcare workers: an achievable quality improvement target
por: Weinerman, Adina S, et al.
Publicado: (2023)

Tetravalent dengue DNA vaccine is not immunogenic when delivered by retrograde infusion into salivary glands
por: El Helou, Guy, et al.
Publicado: (2020)

Recent changes of invasive meningococcal disease in France: arguments to revise the vaccination strategy in view of those of other countries
por: Taha, Muhamed-Kheir, et al.
Publicado: (2020)

COVID-19 vaccine hesitancy among healthcare workers
por: Paris, Christophe, et al.
Publicado: (2021)

Safety, immunogenicity & effectiveness of the COVID-19 vaccine among healthcare workers in a tertiary care hospital
por: Kataria, Sushila, et al.
Publicado: (2022)

Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients
por: Rabinowich, Liane, et al.
Publicado: (2021)

Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ/su): A phase-I, open-label study in Japanese adults
por: Lal, Himal, et al.
Publicado: (2013)

Immunogenicity and safety of a multi-dose quadrivalent inactivated influenza vaccine in individuals aged 6 months to 17 years: a randomized phase III trial
por: Ojeda, Joyce, et al.
Publicado: (2019)

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial
por: Thiem, Vu Dinh, et al.
Publicado: (2021)

Diversity of greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine
por: Tzanakaki, Georgina, et al.
Publicado: (2014)

COVID-19 vaccine confidence and reasons for vaccination among health care workers and household members
por: Ulrich, Angela K., et al.
Publicado: (2022)

Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip®
por: Latreille-Barbier, Mathilde, et al.
Publicado: (2017)

Immunogenicity of third dose of anti-SARS-CoV-2 vaccine co-administered with influenza vaccine: An open question
por: Stefanizzi, Pasquale, et al.
Publicado: (2022)

Prior exposure to an attenuated Listeria vaccine does not reduce immunogenicity: pre-clinical assessment of the efficacy of a Listeria vaccine in the induction of immune responses against HIV
por: Whitney, James B, et al.
Publicado: (2011)

The Effect of Various Stabilizers on Preserving Immunogenicity of Lyophilized Mumps Vaccines
por: Kamali-Jamil, Razieh, et al.
Publicado: (2017)

Distribution of Bexsero® Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: Implications for immunisation
por: Brehony, Carina, et al.
Publicado: (2016)

Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers: A pooled analysis of randomized trials
por: Bryant, Kristina A., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_otjust9su6fskjh9ospag5e0cr